Latest news

• LEO Pharma reports positive results for chronic hand eczema topical treatment

  Hand eczema is the most common skin disorder of the hands and one of the most common types of eczema

• LEO Pharma’s delgocitinib cream shows promise in phase 3 chronic hand eczema study

  There are no topical treatments specifically developed and approved for moderate-to-severe CHE

• Joerg Moeller to head Bayer R&D after operational shake-up

  Bayer is revamping its structure, combining all its R&D research units into one division that will be headed by Joerg Moeller, current head of development. ... Moeller, who has been head of Bayer’s pharma division since 2014, officially takes over the

• Bayer drug-device combo for pneumonia flunks phase III test

  However, the study provides important clinical data for this difficult-to-treat disease,” commented Bayer’s head of development Joerg Moeller.

• Xarelto no better than aspirin in secondary stroke study

  Patients with ESUS currently have limited treatment options and the role of anticoagulants in this area remains uncertain,” said Joerg Moeller, Bayer's head of development.